View in EDS

Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.

Saved in:
Bibliographic Details
Title: Lack of synergy between AR-targeted therapies and PARP inhibitors in homologous recombination-proficient prostate cancer.
Authors: Traphagen NA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215., Wheeler E; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215., Li R; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215., Akhshi T; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215., Ravindranathan R; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215., Alfieri C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215., Lu F; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215., Ahmed B; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215., Tewari AK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215., Balk SP; Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215., Nelson PS; Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109., Corey E; Department of Urology, University of Washington, Seattle, WA 98915., Long H; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215., D'Andrea AD; Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215.; Center for DNA Damage and Repair, Dana-Farber Cancer Institute and Harvard Medical, Boston, MA 02215., Qiu X; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215., Brown M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215.; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215.
Source: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2026 Feb 03; Vol. 123 (5), pp. e2515790122. Date of Electronic Publication: 2026 Jan 27.
Publication Type: Journal Article
Journal Info: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1091-6490
DOI:10.1073/pnas.2515790122